Hims & Hers misses revenue estimates

Telehealth earnings are usually a growth story. This one was a unit-economics story. Hims & Hers reported first-quarter 2026 revenue of $608.1 million on May 11, up 4% from a year earlier, but that still missed consensus near $616.8 million, and the company swung to a GAAP loss of $0.40 a share instead of the small profit analysts expected. (investors.hims.com) The stock fell more than 12% in extended trading because the miss landed right as Hims is remaking its weight-loss business. ### What broke in the quarter? The simple answer is mix. Hims used to benefit from compounded GLP-1 offerings that carried better economics. Now it is pushing more branded GLP-1 drugs, including Wegovy through its new Novo Nordisk partnership, and that changes the math fast — higher drug cost, lower margin, more restructuring noise. (finance.yahoo.com) Gross margin dropped to 65% from 73% a year earlier, and net income flipped to a $92.1 million loss from a $49.5 million profit. ### Why does branded GLP-1 hurt margins? Because Hims is no longer mostly selling a software-like service wrapped around relatively cheap fulfillment. It is increasingly acting as a distribution and care layer for expensive branded drugs. That can still produce revenue growth, but each dollar of sales carries less profit. (investors.hims.com) You can see it in monthly revenue per average subscriber, which fell to $80 from $85 even as subscribers rose to nearly 2.6 million. More users showed up, but the business made less from each one on average. ### Didn’t the company raise guidance? It did, and that is the part making this quarter tricky to read. Hims lifted full-year 2026 revenue guidance to $2.8 billion to $3.0 billion from $2.7 billion to $2.9 billion. (finance.yahoo.com) It also updated adjusted EBITDA guidance to $275 million to $350 million. So management is basically saying the reset is painful now but should set up faster growth later. Investors just did not fully buy that on day one. ### Why are investors skeptical anyway? Because raised revenue guidance is not the same thing as better quality revenue. Some of the optimism depends on international expansion and acquisitions, including the proposed Eucalyptus deal, while the core U.S. transition is still messy. (investors.hims.com) One analyst view in the immediate reaction was that it may be too early for the Novo partnership to meaningfully drive growth on its own. In other words — the future story may be real, but this quarter did not prove it yet. ### How much of this was regulatory pressure? A lot. The FDA has been tightening around compounded copycat GLP-1 products, which pushed Hims away from the cheaper compounded playbook and toward FDA-approved branded drugs. (investors.hims.com) That shift is safer from a regulatory standpoint, but it also strips away the unusually rich margins investors had gotten used to. The company is trading one kind of risk for another — less legal and regulatory overhang, more pressure on profitability. ### What is management betting on now? Management is betting that scale wins. Andrew Dudum and CFO Yemi Okupe are pointing to stronger traffic, broader consumer reach, and a larger platform that can spread technology and operations costs across more specialties and more countries. (finance.yahoo.com) They also said they expect a return to profitability in 2027, not this year. That timeline matters because it tells you this is not a one-quarter cleanup. It is a multi-year rebuild of the model. ### Why does this matter beyond one stock? Because Hims is showing what happens when a consumer-health platform moves from light, high-margin categories into expensive prescription drugs. Revenue can keep growing. Engagement can even improve. (finance.yahoo.com) But the business starts to look less like software and more like healthcare retail — lower margin, more regulation, more dependence on drug makers. That is a much tougher model to impress investors with in one earnings print. ### Bottom line The quarter was not a demand collapse. It was a reality check. Hims & Hers may still build a much bigger weight-loss business, but the branded GLP-1 version of that business looks costlier, slower to monetize, and much less forgiving than the old compounded one. (investors.hims.com) (finance.yahoo.com)